Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?
- PMID: 16256974
- DOI: 10.1016/j.clinbiochem.2005.09.002
Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?
Abstract
Objectives: To evaluate deoxypyridinoline as a resorption marker in phenylketonuria (PKU) and to search for a relationship between deoxypyridinoline, calcium/creatinine index (Ca/Cr I), osteocalcin and bone alkaline phosphatase (BAP).
Methods: This was a transversal analytical study of 46 PKU patients [17.5 (4-38) years]. Deoxypyridinoline and osteocalcin were measured with a chemiluminescent assay and BAP was measured with an immunoradiometric assay.
Results: Deoxypyridinoline was significantly increased in patients aged 7-14 and >18 years old, being associated with age (r=-0.724, P<0.001). Adult patients showed significantly higher Ca/Cr I, which correlates with Phe values for the year prior to the study (P=0.014). Serum BAP was significantly increased in pediatric patients (9-13 years), while it was decreased in adult patients (P=0.003). Decreased osteocalcin levels were found in patients>15 years (P=0.028). Altered deoxypyridinoline and BAP values were related (P=0.042).
Conclusion: PKU patients excreted increased D-Pyr, suggesting high bone resorption. Bone formation seems active in childhood but deteriorates in adult PKU patients. Periodic measurement of D-Pyr and BAP may be useful in the prevention of osteopenia in PKU patients.
Similar articles
-
[Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria].Pol Merkur Lekarski. 2008 Jul;25(145):57-60. Pol Merkur Lekarski. 2008. PMID: 18839616 Polish.
-
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.Eur J Haematol. 2006 May;76(5):399-404. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2520.x. Epub 2006 Feb 15. Eur J Haematol. 2006. PMID: 16480429 Clinical Trial.
-
Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassaemia major.Int J Clin Pract. 2005 Jan;59(1):46-51. doi: 10.1111/j.1742-1241.2005.00358.x. Int J Clin Pract. 2005. PMID: 15707464
-
[Evaluation of cancer-induced bone diseases by bone metabolic marker].Clin Calcium. 2006 Apr;16(4):581- 90. Clin Calcium. 2006. PMID: 16582508 Review. Japanese.
-
[Bone alkaline phosphatase (BAP)].Nihon Rinsho. 2004 Dec;62 Suppl 12:210-4. Nihon Rinsho. 2004. PMID: 15658302 Review. Japanese. No abstract available.
Cited by
-
Recommendations for the nutrition management of phenylalanine hydroxylase deficiency.Genet Med. 2014 Feb;16(2):121-31. doi: 10.1038/gim.2013.179. Epub 2014 Jan 2. Genet Med. 2014. PMID: 24385075 Free PMC article. Review.
-
Bone Status in Patients with Phenylketonuria: A Systematic Review.Nutrients. 2020 Jul 20;12(7):2154. doi: 10.3390/nu12072154. Nutrients. 2020. PMID: 32698408 Free PMC article.
-
Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet.Iran J Pediatr. 2014 Feb;24(1):23-8. Epub 2013 Dec 31. Iran J Pediatr. 2014. PMID: 25793041 Free PMC article.
-
Nutritional issues in treating phenylketonuria.J Inherit Metab Dis. 2010 Dec;33(6):659-64. doi: 10.1007/s10545-010-9043-4. Epub 2010 Feb 12. J Inherit Metab Dis. 2010. PMID: 20151202 Review.
-
Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.PLoS One. 2010 Nov 30;5(11):e14167. doi: 10.1371/journal.pone.0014167. PLoS One. 2010. PMID: 21152388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical